ORTHO-NOVUM 1/35-21 Drug Patent Profile
✉ Email this page to a colleague
When do Ortho-novum 1/35-21 patents expire, and when can generic versions of Ortho-novum 1/35-21 launch?
Ortho-novum 1/35-21 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.
The generic ingredient in ORTHO-NOVUM 1/35-21 is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORTHO-NOVUM 1/35-21?
- What are the global sales for ORTHO-NOVUM 1/35-21?
- What is Average Wholesale Price for ORTHO-NOVUM 1/35-21?
Summary for ORTHO-NOVUM 1/35-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 219 |
| DailyMed Link: | ORTHO-NOVUM 1/35-21 at DailyMed |
US Patents and Regulatory Information for ORTHO-NOVUM 1/35-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortho Mcneil Pharm | ORTHO-NOVUM 1/35-21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 017489-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
